ACADIA Pharmaceuticals Inc.
ACADAcadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, California.
Drugs in Pipeline
11
Phase 3 Programs
7
Upcoming Catalysts
1
Next Catalyst
Aug 5, 2026
7wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
ACP-204
Lewy Body Dementia Psychosis
Pimavanserin 34 mg
Dementia-related Psychosis
Trofinetide
Rett Syndrome
Pimavanserin tartrate (ACP-103)
Parkinson's Disease Psychosis
Carbetocin
Hyperphagia in Prader-Willi Syndrome
Pimavanserin
Agitation and Aggression in Alzheimer's Disease
pimavanserin tartrate
Parkinson's Disease Psychosis
ACP-103
Hallucinations
ACP-104
Schizophrenia
ACP-044 Dose A
Acute Postoperative Pain
ACP-211
Major Depressive Disorder (MDD)
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
ACP-204 | Phase 3 | Lewy Body Dementia Psychosis | - | - |
Pimavanserin 34 mg | Phase 3 | Dementia-related Psychosis | - | - |
Trofinetide | Phase 3 | Rett Syndrome | - | - |
Pimavanserin tartrate (ACP-103) | Phase 3 | Parkinson's Disease Psychosis | - | - |
Carbetocin | Phase 3 | Hyperphagia in Prader-Willi Syndrome | - | - |
Pimavanserin | Phase 3 | Agitation and Aggression in Alzheimer's Disease | - | - |
pimavanserin tartrate | Phase 3 | Parkinson's Disease Psychosis | - | - |
ACP-103 | Phase 2 | Hallucinations | - | - |
ACP-104 | Phase 2 | Schizophrenia | - | - |
ACP-044 Dose A | Phase 2 | Acute Postoperative Pain | - | - |
ACP-211 | Phase 2 | Major Depressive Disorder (MDD) | - | - |
Parkinson's Disease Psychosis
2 drugs in this indication
Acute Postoperative Pain
1 drug in this indication
Agitation and Aggression in Alzheimer's Disease
1 drug in this indication
Rett Syndrome
1 drug in this indication
Hallucinations
1 drug in this indication
Schizophrenia
1 drug in this indication
Lewy Body Dementia Psychosis
1 drug in this indication
Hyperphagia in Prader-Willi Syndrome
1 drug in this indication
Adjunctive Treatment of Major Depressive Disorder
1 drug in this indication
Dementia-related Psychosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)